Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
670 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05337189 | A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China | unknown | — | 482 | Creative Biosciences (Guangzhou) Co., Ltd.INDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 |
| clinicaltrials |
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 | clinicaltrials |
| NCT06564363 | The Efficacy of the IUrisure for Detection of Recurrent Urothelial Carcinoma | unknown | — | 148 | Wuhan Ammunition Life-tech Co., LtdINDUSTRY | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06215976 | The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer | unknown | Phase 4 | 78 | Cairo UniversityOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT01890590 | A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma | unknown | N/A | 46 | Beth Israel Deaconess Medical CenterOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06550947 | ALDOA Expression in Bladder Urothelial Carcinoma | unknown | — | 50 | Assiut UniversityOTHER | 0 | Aug 13, 2024 | clinicaltrials |
| NCT06548867 | Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib(CABOGEN) | unknown | — | 80 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT04503148 | Anesthesia and Cancer Study: Renal Cell Carcinoma | unknown | N/A | 562 | Seoul National University HospitalOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT06428708 | [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma | unknown | Early Phase 1 | 30 | Western UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06427993 | Urine DNA Methylation Detection for Hematuria Evaluation | unknown | — | 71 | Changhai HospitalOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06424080 | Oncological and Perioperative Outcomes of Laparoscopic Versus Robotic Partial Nephrectomy for Treatment of Renal Tumors. | unknown | N/A | 20 | Menoufia UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05024318 | NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma(NAPSTER) | unknown | Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06416319 | Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct)(PreAct) | unknown | N/A | 164 | Universitätsmedizin MannheimOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05354102 | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | unknown | Phase 1 | 11 | Biomica Ltd.INDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT04486781 | A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma | unknown | Phase 2 | 38 | Vasgene Therapeutics, IncINDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT06391879 | Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma | unknown | — | 300 | Peking University First HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06363123 | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | unknown | — | 2,700 | Beijing Friendship HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT04387500 | Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma | unknown | Phase 2 | 41 | West China HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06342323 | The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy(ONFM-SBRT) | unknown | — | 57 | Peking University Third HospitalOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06322745 | Thulium Beam Coagulation Versus Suture Renorrhaphy for Hemostasis of Tumor Bed in Laparoscopic Partial Nephrectomy | unknown | N/A | 30 | Al-Azhar UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06321640 | Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.(POSITive) | unknown | — | 265 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06317298 | Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy | unknown | N/A | 36 | Peking University First HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT03549715 | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma(NEMIO) | unknown | Phase 1 / Phase 2 | 121 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04492293 | An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer | unknown | Phase 2 | 115 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05297552 | A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06235268 | Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma | unknown | — | 1,000 | Federation of Italian Cooperative Oncology GroupsOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06182644 | Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors(FAPI) | unknown | N/A | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT04994197 | Urothelial Tumor Risk Genes Detection With Genetron Uro V1 and LC-WGS | unknown | — | 970 | Ruijin HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06182735 | CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma | unknown | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06178601 | A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma | unknown | Phase 2 | 36 | Shanxi Province Cancer HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT02969083 | Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma(URANUS) | unknown | Phase 2 | 200 | The European Uro-Oncology GroupOTHER | 3 | Dec 18, 2023 | clinicaltrials |
| NCT03108703 | Assessment of QoL and Outcomes With SBRT for RCC(AQuOS-RCC) | unknown | N/A | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04040530 | Patient Reported Outcome After Nephron Sparing Treatment of Small Renal Tumours | unknown | — | 187 | Region of Southern DenmarkOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06134700 | Low Pressure Versus Standard Pressure Pneumoperitoneum in Laparoscopic Nephrectomy | unknown | N/A | 44 | Institute of medicine, Maharagjung medical campusOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06129955 | Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06120413 | 18F-LN1 PET/CT in Urothelial Carcinomas | unknown | — | 30 | Sichuan Provincial People's HospitalOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06113367 | Immunotherapy in Upper Tract Urothelial Carcinoma(VESUVIO) | unknown | — | 350 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Nov 2, 2023 | clinicaltrials |
| NCT05259319 | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)(IMMUNOs-SBRT) | unknown | Phase 1 | 92 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05176145 | Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test(DMIA) | unknown | N/A | 400 | VitadxOTHER | 3 | Oct 13, 2023 | clinicaltrials |
| NCT06074484 | A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06049030 | A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma | unknown | Phase 1 | 190 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT05534854 | Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes | unknown | — | 500 | RenJi HospitalOTHER | 1 | Aug 31, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Feb 13, 2025source: clinicaltrials